comparemela.com

Latest Breaking News On - Axi cel - Page 1 : comparemela.com

Recent Data on Axi-Cel in Lymphoma

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.

Lori-leslie
Jamesk-mccloskey
Gloria-leslie
Peer-exchange
Research-programs
John-theurer-cancer-center
Hackensack-university-medical-center
Hackensack-university-medical
Associate-professor
Indolent-lymphoma
Lymphoma

Choosing CAR T-cells as Third-line and Beyond Therapy for FL

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

Jennifer-crombie
Recent-updates
Follicular-lymphoma
Mantle-cell-lymphoma
Beyond-therapy
Fl
Cart-cell-therapy
Head-to-trial
Axi-cel
Spfs
Tisa-cel

Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma.

Gloria-leslie
Chronic-lymphocytic-leukemia-research-programs
Hackensack-meridian-school-of-medicine
John-theurer-cancer-center
Indolent-lymphoma
Hackensack-meridian-school
D
John-theurer-cancer-center
Dlbcl
Axi-cel
Elderly-patients

CAR T-cells as Third-line and Beyond Therapy for FL

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Bijal-shah
Recent-updates
Follicular-lymphoma
Mantle-cell-lymphoma
Beyond-therapy
Fl
Cmcl
Cart-cell-therapy
Bendamustine
Zuma-5
Axicabtagene-ciloleucel

Axi-Cel Provides Sustained Response in High-Risk Large B-cell Lymphoma

Patients with high-risk large B-cell lymphoma experienced durable responses when treated with first-line axicabtagene ciloleucel, according to results from the phase 2 ZUMA-12 trial.

Julio-chavez
Lymphoma-section
Malignant-hematology
Moffitt-cancer-center
Axi-cel
Zuma-12-trial
High-risk-largeb-cell-lymphoma
Yescarta
Ash-annual-meeting

vimarsana © 2020. All Rights Reserved.